Synopsis of recent research by authors named "Shelby Umland"
Recent research by Shelby Umland has focused on the development of potent TNF-α converting enzyme (TACE) inhibitors, specifically through the design of various hydantoin-based compounds that exhibit sub-nanomolar potency and favorable pharmacokinetic profiles.
Umland's work has addressed formulation challenges of lead compounds by exploring prodrug approaches, ultimately aiming to enhance their therapeutic viability for treating inflammatory diseases.
Additionally, Umland has contributed to the pharmacological characterization of various receptors, including the α2C-adrenoceptor and the role of ADAM family enzymes in immunological responses, demonstrating a broad interest in medicinal chemistry and receptor biology.